ReviewTrends in molecular medicine2018
Pluripotent Stem Cell Platforms for Drug Discovery.
Review in Trends in molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- Organoid-on-a-chip (OrgOC): Advancing cystic fibrosis research.Materials today. Bio · 2025Review
- Remodeling and repair of the damaged brain: the potential and challenges of organoids for ischaemic stroke.Journal of translational medicine · 2025Review
- Article
- Unraveling the impact of ZZZ3 on the mTOR/ribosome pathway in human embryonic stem cells homeostasis.Stem cell reports · 2024Article
- Metabolic Quadrivalency in RSeT Human Embryonic Stem Cells.bioRxiv : the preprint server for biology · 2024Article
- Potential Application of Intestinal Organoids in Intestinal Diseases.Stem cell reviews and reports · 2024Review
- Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis.Children (Basel, Switzerland) · 2022Review
- Dextran sulfate prevents excess aggregation of human pluripotent stem cells in 3D culture by inhibiting ICAM1 expression coupled with down-regulating E-cadherin through activating the Wnt signaling pathway.Stem cell research & therapy · 2022Article
- Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic.NPJ Regenerative medicine · 2021Review
- Imaging therapeutic peptide transport across intestinal barriers.RSC chemical biology · 2021Review
- Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids.Nature cell biology · 2021Review
- Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening.Scientific reports · 2021Article
- Human Embryo Models and Drug Discovery.International journal of molecular sciences · 2021Review
- Recent Advances in Electrochemical Sensors for the Detection of Biomolecules and Whole Cells.Biomedicines · 2020Review
- A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids.eLife · 2020Article
- Trends in the development of human stem cell-based non-animal drug testing models.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2020Review
- Radiation Induces Pulmonary Fibrosis by Promoting the Fibrogenic Differentiation of Alveolar Stem Cells.Stem cells international · 2020Article
- Genomic stability at the coding regions of the multidrug transporter geneCancer drug resistance (Alhambra, Calif.) · 2020Article
- Phenotype and target-based chemical biology investigations in cancers.National science review · 2019Article
- Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.Drug discovery today · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Use of human pluripotent stem cells (hPSCs) and their differentiated derivatives have led to recent proof-of-principle drug discoveries, defining a pathway to the implementation of hPSC-based drug discovery (hPDD). Current hPDD strategies, however, have inevitable conceptual biases and technological limitations, including the dimensionality of cell-culture methods, cell maturity and functionality, experimental variability, and data reproducibility. In this review, we dissect representative hPDD systems via analysis of hPSC-based 2D-monolayers, 3D culture, and organoids. We discuss mechanisms of drug discovery and drug repurposing, and roles of membrane drug transporters in tissue maturation and hPDD using the example of drugs that target various mutations of CFTR, the cystic fibrosis transmembrane conductance regulator gene, in patients with cystic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.